Literature DB >> 21926097

An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study.

J D Peterson1, M P Goldman.   

Abstract

OBJECTIVES: In sclerotherapy, carbon dioxide (CO(2)) or room air can be employed by phlebologists for foam creation. We compared room air (RA) and carbon dioxide in treating reticular leg veins with foam sclerotherapy.
METHODS: Twenty patients were randomly treated with RA- or CO(2)-created sodium tetradecyl sulphate (STS) foam. Concentration and volume of STS, side-effects and efficacy were determined.
RESULTS: There was no difference in the efficacy, local side-effects or distant side-effects between RA and CO(2) foam in the treatment of reticular leg veins. The total volume of foam sclerosant required for treatment was greater with CO(2) compared with RA (P value = 0.01).
CONCLUSION: No differences were found in efficacy or side-effects between RA- and CO(2)-foam sclerotherapy for reticular leg veins. CO(2) foam's shorter half-life was hypothesized to be responsible for larger total volumes of CO(2) foam sclerosant.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926097     DOI: 10.1258/phleb.2011.010073

Source DB:  PubMed          Journal:  Phlebology        ISSN: 0268-3555            Impact factor:   1.740


  3 in total

Review 1.  Treatment for telangiectasias and reticular veins.

Authors:  Luis Cu Nakano; Daniel G Cacione; Jose Cc Baptista-Silva; Ronald Lg Flumignan
Journal:  Cochrane Database Syst Rev       Date:  2021-10-12

Review 2.  Management of Venous Malformations.

Authors:  Michael Acord; Abhay Srinivasan
Journal:  Semin Intervent Radiol       Date:  2021-06-03       Impact factor: 1.780

3.  In vitro and ex vivo evaluation of the biological performance of sclerosing foams.

Authors:  Elisabetta Bottaro; Jemma A J Paterson; Luciano Quercia; Xunli Zhang; Martyn Hill; Venisha A Patel; Stephen A Jones; Andrew L Lewis; Timothy M Millar; Dario Carugo
Journal:  Sci Rep       Date:  2019-07-08       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.